ArticleClinical pharmacology and therapeutics2019
A PK/PD Analysis of Circulating Biomarkers and Their Relationship to Tumor Response in Atezolizumab-Treated non-small Cell Lung Cancer Patients.
Article in Clinical pharmacology and therapeutics, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed, 38 citations in OpenAlex.
- Mechanistic Learning for Predicting Survival Outcomes in Head and Neck Squamous Cell Carcinoma.CPT: pharmacometrics & systems pharmacology · 2025Trial
- Insights into the Complexities of Pharmacotherapy Parameters in Artificial Intelligence Models for Drug Selection, Precision Personalised Medicine and Optimal Therapeutic Outcomes.Pharmaceutics · 2026Review
- Multitask learning of longitudinal circulating biomarkers and clinical outcomes: identification of optimal machine-learning and deep-learning models.BMC medical informatics and decision making · 2026Article
- Review of Existing Approaches and Potential Role of Pharmacometrics in the Interpretation of Prognostic Circulating Serum Biomarkers in Advanced NSCLC.Clinical and translational science · 2026Review
- Exposure-response relationship of sintilimab in advanced gastric cancer: insights from time-dependent pharmacokinetics and biomarker integration for precision immunotherapy.Frontiers in pharmacology · 2026Review
- Article
- Article
- An overview of statistical methods for biomarkers relevant to early clinical development of cancer immunotherapies.Frontiers in immunology · 2024Review
- Biomarkers and computational models for predicting efficacy to tumor ICI immunotherapy.Frontiers in immunology · 2024Review
- Model-informed drug development of autologous CAR-T cell therapy: Strategies to optimize CAR-T cell exposure leveraging cell kinetic/dynamic modeling.CPT: pharmacometrics & systems pharmacology · 2023Review
- The Role of IL-18 in P2RX7-Mediated Antitumor Immunity.International journal of molecular sciences · 2023Review
- Avelumab Dose Selection for Clinical Studies in Pediatric Patients with Solid Tumors.Clinical pharmacokinetics · 2022Article
- Model-Based Characterization of the Bidirectional Interaction Between Pharmacokinetics and Tumor Growth Dynamics in Patients with Metastatic Merkel Cell Carcinoma Treated with Avelumab.Clinical cancer research : an official journal of the American Association for Cancer Research · 2022Article
- Results of a Dose-Finding Phase 1b Study of Subcutaneous Atezolizumab in Patients With Locally Advanced or Metastatic Non-Small Cell Lung Cancer.Clinical pharmacology in drug development · 2021Article
- The Role of Mathematical Models in Immuno-Oncology: Challenges and Future Perspectives.Pharmaceutics · 2021Review
- The association between adverse events and outcome under checkpoint inhibitors: Where is the deal?Translational oncology · 2021Review
- Progress and Opportunities to Advance Clinical Cancer Therapeutics Using Tumor Dynamic Models.Clinical cancer research : an official journal of the American Association for Cancer Research · 2020Review
- Tumor Time-Course Predicts Overall Survival in Non-Small Cell Lung Cancer Patients Treated with Atezolizumab: Dependency on Follow-Up Time.CPT: pharmacometrics & systems pharmacology · 2020Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
To assess circulating biomarkers as predictors of antitumor response to atezolizumab (anti-programmed death-ligand 1 (PD-L1), Tecentriq) serum pharmacokinetic (PK) and 95 plasma biomarkers were analyzed in 88 patients with relapsed/refractory non-small cell lung cancer (NSCLC) receiving atezolizumab i.v. q3w (10-20 mg/kg) in the PCD4989g phase I clinical trial. Following exploratory analyses, two plasma biomarkers were chosen for further study and correlation with change in tumor size (the sum of the longest diameter) was assessed in a pharmacokinetic/pharmacodynamic (PK/PD) tumor modeling framework. When longitudinal kinetics of biomarkers and tumor size were modeled, tumor shrinkage was found to significantly correlate with area under the curve (AUC), baseline factors (metastatic sites, liver metastases, and smoking status), and relative change in interleukin (IL)-18 level from baseline at day 21 (RCFB
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.